

April 24, 2014

**Notification on the commencement of Phase I clinical trial of HP-3070 in the United States
(a transdermal tape formulation for the treatment of schizophrenia)**

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu city, Saga prefecture, Japan; President and CEO: Hiroataka Nakatomi, hereinafter referred to as “Hisamitsu”) hereby announces the commencement of the Phase I clinical trial on a transdermal tape formulation for the treatment of schizophrenia in the United States (Development code: HP-3070, hereinafter referred to as “the product”).

The clinical trial will be conducted by a subsidiary in the United States of the Company, Noven Pharmaceuticals, Inc. (Head Office: Florida, U.S.A.; hereinafter referred to as “Noven”).

The product is a systemic transdermal tape formulation developed by use of Hisamitsu’s TDDS (Transdermal Drug Delivery System) technology. It is expected to be a new option for the treatment of schizophrenia by continuous blood concentration and effectiveness.

The Phase I clinical trial is to study pharmacokinetics and safety in patients with schizophrenia.

Hisamitsu aims to initiate a Phase II clinical trial during FY 2015 in the United States.

About Noven

Noven is a pharmaceutical company engaged in the research, development, manufacturing, marketing, and sale of prescription pharmaceutical products. Noven is committed to developing and offering products and technologies that meaningfully benefit patients, its customers, and its industry partners. Noven is a stand-alone operating subsidiary of Hisamitsu and serves as Hisamitsu’s U.S. growth platform in prescription pharmaceuticals.